ArticleJournal of clinical and experimental hematopathology : JCEH2026
Synchronous diffuse large B-cell lymphoma and gynecological malignancy treated with paclitaxel and carboplatin: A report of two cases.
Article in Journal of clinical and experimental hematopathology : JCEH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) can occur at various sites and is rarely diagnosed as synchronous multiple primary malignancies. A treatment approach for this synchronous malignancy has not been established. Here, we report two cases of synchronous DLBCL and gynecological malignancy treated with the paclitaxel and carboplatin (TC) regimen. Patient #1: A 67-year-old female presented with right axillary lymphadenopathy. A computed tomography (CT) revealed a hepatic mass and an ovarian tumor. Biopsy of the lymphadenopathy diagnosed DLBCL (stage I). Ovarian and peritoneal biopsies confirmed ovarian cancer (stage IVB, peritoneal dissemination, and liver metastasis). She received 6 cycles of TC chemotherapy for ovarian cancer, followed by surgery (pT3cN0M1) and an additional 2 cycles of TC. A complete metabolic response (CMR) of both malignancies was confirmed 1 year later. Patient #2: A 77-year-old female presented with left knee discomfort. Biopsy of a left femoral tumor diagnosed DLBCL (stage I). PET-CT revealed abnormal fluorodeoxyglucose uptake in the left femur and in the uterus, with an endometrial biopsy confirming endometrial cancer. She received radiation therapy for DLBCL, followed by surgery for endometrial cancer (pT1bNxM0). Postoperatively, 6 cycles of TC chemotherapy were performed, and she achieved a CMR. No Grade 3/4 nonhematologic adverse events were observed in both patients. In conclusion, the TC regimen was safely administered in our two patients. In one of them, TC therapy alone was effective for DLBCL. The clinical courses may provide a valuable reference for the management of similar patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.